The pandemic caused by the novel coronavirus SARS-CoV-2 manifests clinically in different ways. Most patients infected with SARS-CoV-2 exhibit mild to moderate symptoms and approximately 40 - 50% are asymptomatic. However, some patients develop severe disease that manifests as the acute respiratory distress syndrome (ARDS), multi-organ failure and/or septic shock. The virus is transmitted via aerosol, fomite and possibly faecal-oral routes. Some individuals develop coagulation-related pathologies and multiple-organ failure, which sets COVID-19 apart from hyperinflammatory states seen in other diseases.[1]

Most individuals who are admitted to hospital present with pneumonia and hypoxaemia.[2] Some individuals develop coagulation-related pathologies and multiple-organ failure, which sets COVID-19 apart from hyperinflammatory states seen in other diseases.[2]

Methods

PubMed and other databases were accessed using the search words ‘COVID-19 AND pathophysiology’, and ‘COVID-19 AND treatment AND therapeutic strategies’. The authors then evaluated published studies on the pathophysiology, severity and therapeutic options based on data from these sources. This is not an exhaustive systematic review, or a meta-analysis, but rather a descriptive review, in an ever-changing field, of some of the key pathogenetic mechanisms to have emerged in a disease whose existence we have known about for less than a year.

Pathogenesis of COVID-19

SARS-CoV-2 infects the host by binding to angiotensin-converting enzyme 2 (ACE-2). There is now evidence that the virus infects multiple pulmonary cell types, including bronchial epithelium, with the virus being detected in abundance in ciliated cells, non-ciliated cell types, including bronchial epithelium, with the virus being detected in abundance in ciliated cells, non-ciliated

Immune dysregulation

Following infection, the host attempts to eliminate the virus by inducing an antiviral immune response, which includes both innate and adaptive immune systems.[18] The innate immune response is invoked at the first encounter with the virus and provides an initial mechanism for eliminating the pathogen. However, if the response is defective, the virus will proliferate and cause widespread damage to affected tissues.[19] Infected tissues undergo pyroptosis, which results in the release of damaged associated molecular patterns (DAMPs). These molecular patterns are recognised as 'foreign' by epithelial cells, endothelial cells and alveolar macrophages, which results in matrix metalloproteinase inducer CD147,[21] which are present in vascular endothelial cells, arterial smooth-muscle cells and other cell types. Descriptive studies on the presence of ACE-2 and other (co)receptor proteins and/or transcripts[18] imply that they may be necessary but not that they are sufficient for viral binding. As a result of viral binding to ACE-2, concern has been expressed about using renin-angiotensin-aldosterone system inhibitors, such as angiotensin II receptor blockers (ARBs) and ACE inhibitors for the treatment of hypertension in COVID-19 patients.[11,12] However, two large studies have demonstrated that there is no evidence for an increased risk of COVID-19 as a result of ACE inhibitor or ARB treatment.[14,15] The American Heart Association has stated that ‘Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician.’[16] The hyperinflammatory state that characterises COVID-19 appears to be linked in part to endothelial dysfunction which may result from viral binding to endothelial and pulmonary vascular smooth-muscle cell ACE-2 receptors.[23,24] Recent evidence has shown that interleukin (IL)-6, which plays an important role in the development and progression of the inflammatory process during viral infection, can be induced by angiotensin II through a mineralocorticoid receptor-dependent mechanism, contributing to the hyperinflammatory state.[17]
an uncontrolled innate inflammatory response in the lungs. This is mediated by pro-inflammatory cytokines.\textsuperscript{[19-20]}

One of the consequences of SARS-CoV-2 infection is the activation of neutrophils that release neutrophil extracellular traps (NETs).\textsuperscript{[21]} NETs are comprised of nuclear and mitochondrial DNA and protein material from nuclear chromatin and cytosolic granules. One variant of NET, termed suicidal NETosis, results in cell death and the release of reactive oxygen species. Various molecules can promote this type of NET, including DAMPs. Damaged neutrophils have a negative redox potential that maintains endogenous self-antigens, such as high-mobility group box 1 (HMGB1) in a fully reduced form (fr-HMGB1). HMGB1 promotes activation of the receptor for advanced glycation end products (RAGE), which further triggers neutrophil-mediated inflammation.\textsuperscript{[22]} Activation of toll-like receptor 4 (TLR-4) in turn acts as a procoagulant factor through platelet stimulation of this receptor.

The induction of a proinflammatory process is reflected in raised plasma concentrations of a number of cytokines and chemokines which include IL-1 beta (IL-1β), IL-1RA, IL-6, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon-gamma (IFN-γ), IFN-γ inducible protein (IP)-10, monocyte chemotactic protein (MCP)-1, monocyte inhibitory protein (MIP)-1A, MIP-1B, platelet-derived growth factor (PDGF), tumour necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF).\textsuperscript{[1,3,8-22,24]} These cytokines and chemokines drive inflammation. In mild diseases with limited inflammation, this pro-inflammatory state results in the production of neutralising antibodies by plasma cells driven by virus-specific T cells, and eventually progresses to eradication of the virus and recovery. However, in severe COVID-19 there is an exaggerated degree of inflammation which is deleterious to the host.

In COVID-19, the accumulation of pro-inflammatory cytokines may result in the cytokine release syndrome (CRS or ‘cytokine storm’) with systemic inflammation and damage to the respiratory infrastructure, as well as a hypercoagulable state as a consequence of endothelial injury. In patients with more severe disease, higher levels of IL-2, IL-6, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1A and TNF-α have been observed compared with patients with milder infection and those who do not require admission to an intensive care unit (ICU).\textsuperscript{[25]}

Recent evidence indicates that the surge of cytokines thought to be the driver of the CRS in COVID-19 may not be as high as is seen in other causes of ARDS, and the CRS itself lacks a clear definition with some authors denying its existence. In essence, the presence of immune mediators such as chemokines, interferons, TNF-α, interleukins and others is part of a fundamental immune response needed for innate infection control. It has been proposed that in the CRS, these immune mediators are raised to levels that are detrimental to the host. Of particular interest is IL-6, a key mediator of acute inflammation, which has gained much attention over the course of the pandemic. IL-6 has become a therapeutic target for COVID-19. In randomised clinical trials conducted by the National Heart, Lung and Blood Institution’s ARDS Network, it was reported that patients with severe disease who develop ARDS due to COVID-19 have IL-6 levels 10 - 40-times higher than the upper limit of normal.\textsuperscript{[26]} The phenotype associated with typical ARDS manifests as elevated plasma levels of pro-inflammatory cytokines, an increased propensity to shock and poor clinical outcomes. While the phenotype in COVID-19-related ARDS is consistent with what is expected in a cytokine storm, IL-6 levels in ARDS due to other causes are 10 - 200 times higher than those seen in ARDS due to COVID-19, casting doubt on the presence of a CRS in COVID-19.\textsuperscript{[27]} There is a need to identify patients in whom targeted immunotherapeutic monoclonal antibodies are effective, and to determine biomarkers that could potentially predict the response, to further understand the CRS in COVID-19.\textsuperscript{[28]}

Evidence for macrophage involvement in the pathogenesis of SARS-CoV-2 is undisputed, and it has been suggested that macrophages in the lungs and other organs in COVID-19 are newly derived from circulating monocytes rather than specialised local pre-existing resident tissue macrophages. Circulating monocytes exit the bone marrow via the CC chemokine receptor 2 (CCR2). Trials targeting the chemokine receptors (involved in regulation of monocytes and in T-cell migration) are ongoing.\textsuperscript{[29]}

Coronaviruses are different from other respiratory viruses in that they induce interferons. INF-α and INF-β can drive antiviral immunity, but dysregulated release leads to extensive pathology as seen in patients with severe COVID-19. Normally, interferons mainly have antiviral activity, activating natural killer (NK) cells and macrophages and upregulating the expression of major histocompatibility complex (MHC) antigens which facilitate binding of the virus to T cells. Whereas INF-α and INF-β are expressed almost everywhere, INF-λ affects mostly epithelial cells and has an effect on T-helper type 2 (TH2) cells; it is also immunosuppressive. As a therapeutic intervention, blocking this cytokine might potentially prevent the CRS.\textsuperscript{[27]} The unchecked production of INF-γ also leads to dysregulated macrophage activation. Clinical trials assessing the effects of INF-γ blockade in patients with respiratory distress and severe disease are under way.\textsuperscript{[27]}

**Host factors promoting COVID-19 severity**

**Age**

Advanced age (>60 years) and certain comorbidities are presumed to contribute to a dysregulated immune response, which is less efficient at pathogen elimination.\textsuperscript{[20]} This process describes immunosenescence and has been attributed to altered dendritic cell maturation and defective T-cell activation. With increased age, the combination of thymic degeneration and the continuous conversion of naïve T cells into memory T cells as a result of antigen challenge results in the T-cell receptor repertoire being reduced and replaced by oligoclonal memory T cells.\textsuperscript{[29]} Age-related alterations in the T-cell repertoire have significant clinical implications, since naïve T cells have mostly been replaced. This is of particular concern in the production of a vaccine for COVID-19 if one draws a parallel with the poor outcomes seen with the yearly influenza vaccine among the elderly.\textsuperscript{[30]} Ageing is considered to be a pro-inflammatory state. Taken together, changes seen with advanced age including a dysregulated immune response and an augmented inflammatory state can exacerbate disease severity.\textsuperscript{[20]} A recent study has shed light on the effects of age on pulmonary defence mechanisms: specific factors in the antioxidant defence system of alveolar type II cells, including superoxide dismutase 3 and activating transcription factor 4 (an endoplasmic reticulum stress sensor), become less effective with age.\textsuperscript{[28]}

In contrast to those of advanced age, children are less severely affected despite having higher viral titres; 50% of individuals less than 18 years of age experience mild disease or are asymptomatic, and less than 6% develop severe symptomatic infection. Mortality in this group is extremely low in comparison with adults and especially the elderly.\textsuperscript{[31]}

**Comorbidities**

Comorbidities appear to be the most consistent feature in individuals with severe disease, with more than 30% of symptomatic individuals...
having a comorbid condition. The vast majority of severe COVID-19 cases and deaths occur in individuals with an underlying chronic condition including obesity, diabetes, chronic respiratory disease, diseases of the cardiovascular system (especially hypertension) and malignancy. These conditions are all associated with an impaired immune response, and when superimposed on a hyperinflammatory state, contribute to disease severity. These comorbidities are also associated with endothelial dysfunction.

In addition, there is increasing evidence that a deficiency in nicotinamide adenine dinucleotide (NAD\(^+\)) is associated with disease severity in COVID-19. Hypertension, obesity, diabetes and advanced age are all associated with oxidative stress and pre-existing depletion of NAD\(^+\). When patients with comorbidities are infected with SARS-CoV-2, this reduces NAD\(^+\)-dependent silent information regulator 1 (SIRT1) production, modifies the inflammatory response and, together with other members of the sirtuin family, constitutes part of the primary defence against DNA and RNA viral pathogens. Nutritional support with NAD\(^+\) precursors and SIRT1 activators (including zinc and nicotinic acid) has a rational scientific basis.

Genetic factors
HLA haplotypes and SARS-CoV-2 infection

Human leukocyte antigen (HLA) diversity is a product of selective pressure during pathogen co-evolution. Genetic susceptibility to various infectious diseases such as tuberculosis, leprosy, HIV, hepatitis B and influenza has been well established. This susceptibility is conferred in part by HLA loci. For example, HLA-A*11, HLA-B*35, and HLA-DRB1*10 confer susceptibility to influenza (H1N1)pdm09 infection. Hence it is important to identify possible HLA haplotypes which may be associated with an immune response to SARS-CoV-2. This information will be beneficial for vaccine development. It may also help in developing novel treatment strategies.

ARDS

Complex genetic and environmental risk factors contribute to the development of ARDS. More than 80 genes have been implicated, with the most common variants being found in the genes for IL-6, IL-10, ACE, IL-1 receptor antagonist (IL1RN), mannose-binding lectin 2 (MBL-2), nicotinamide phosphoribosyltransferase (NAMPT) and VEGF-A. These gene products play an important role in the immune response, chemotaxis and cell proliferation. Since most of this information has been extrapolated from European populations, similar studies in African populations (which have extensive genomic diversity) would be important.

Prior to COVID-19 and in other diseases with ARDS, in a genome-wide association study Christie et al.\(^{[40]}\) identified variants associated with ARDS in the genes for tyrosine phosphatase receptor type f polyepitope interacting protein (liprin) and alpha 1 (PPIF1A1), as well as genes encoding IL-10, angiopoietin 2 (ANGPT2), Fas cell surface death receptor (FAS) and myosin light chain kinase (MYLK). Lee et al.\(^{[41]}\) identified MYLK to be associated with ARDS and ‘ventilator free days’, linking MYLK to ARDS susceptibility. Shortt et al.\(^{[42]}\) presented three genomic variants that may be involved in enhancing the susceptibility, severity and clinical outcome of ARDS that include arylsulfatase D gene (ARSD), X Kell blood group complex subunit related family member 3 gene (XKR3) and zinc finger protein 335 (ZNF335).

COVID-19

A genome-wide analysis study (GWAS) in Italian and Spanish patients with confirmed SARS-CoV-2 found that loci on chromosomes 3 and 9 were linked to SARS-CoV-2-induced respiratory failure.\(^{[43]}\) These loci include: rs11385942 insertion-deletion GA or G variant at locus 3p21.31 and rs657152 A or C SNP at locus 9q34.2.\(^{[44]}\) The association signal at locus 3p21.31 consists of 6 genes that include CCR9, CXCR6, FCYCO1, LZTFL1, SL6A20 and XCR1. Rs11385942 contains the risk allele GA and has been linked to the reduced expression of CXCR6 and increased expression of SL6A20 and LZTFL1, which is highly expressed in pulmonary bronchial and alveolar cells in humans.\(^{[45]}\)

When patients on mechanical ventilation were compared with those on supplemental oxygenation, the former were more likely to have the 3p21.31 (rs11385942) risk allele.\(^{[46]}\) This suggests that the 3p21.31 locus could be involved in enhanced susceptibility to more severe disease. This study also showed that patients with blood group A were found to be at a higher risk of developing SARS-CoV-2 compared with other blood groups, while blood group O had a protective effect when compared with other blood groups. Two subsequent studies based on clinical data and outcomes, but which did not involve a GWAS, yielded similar outcomes. Hoilend et al.\(^{[47]}\) reported that patients with blood group A or AB had an increased risk for requiring mechanical ventilation, continual renal replacement therapy and prolonged ICU stay when compared with patients with O and B blood groups, while Barnkob et al.\(^{[48]}\) reported that ABO blood groups could define susceptibility to infection (with O blood group being protective) but not hospitalisation or death from COVID-19. However, the possible role of blood groups in determining COVID-19 susceptibility and severity has been called into question.\(^{[49]}\)

Other contributors to disease severity and complications of SARS-CoV-2 infection

The presence of ACE-2 receptors on endothelial cells, pericytes and smooth-muscle cells in most organs suggests that SARS-CoV-2, once present in the circulation, may easily spread to all body systems. A recent study of postmortem lung tissues from patients who died from COVID-19 and influenza (H1N1) found a significant number of ACE-2-positive endothelial cells and significant morphological changes with disruption of intercellular junctions, cell swelling, and a loss of contact with the basement membrane.\(^{[50]}\) These findings suggest that endothelial dysfunction, including systemic vasculitis and endothelial cell apoptosis, contributes to the increased risk of developing venous thromboembolic disease and inflammation in various organs in COVID-19.\(^{[51]}\) It should be borne in mind, as indicated above, that ACE-2 may be necessary but not sufficient for SARS-CoV-2 entry; caution should therefore be employed in interpreting localisation data.

It is also probable that, as with other infectious diseases, SARS-CoV-2 can activate coagulopathy through inflammatory responses. Platelet-dense granules contain polyphosphates which are secreted upon activation.\(^{[52]}\) Polyphosphates released from activated platelets accelerate factor V activation, inhibit the anticoagulant activity of tissue factor pathway inhibitor, promote factor XI activation by thrombin, and contribute to the synthesis of thicker fibrin strands that are resistant to fibrinolysis.\(^{[53]}\) This suggests a link between the immune system and the coagulation cascade in COVID-19, as with all sepsis aetiologies.

In addition, a new mechanism has been described in which ACE-2 receptor-bound SARS-CoV-2 induces luminal expression of tissue factor (TF). TF then binds to circulating coagulation factor VII, resulting in production of excess thrombin and fibrin and increased intrinsic clot formation.\(^{[54]}\) A number of cytokines (primarily TNF-α) upregulate NAD phosphate (NADPH) oxidase and nuclear factor-kappa B (NF-κ B) to induce TF production in endothelial cells.\(^{[55]}\)
Inflammation also results in activated pulmonary vascular endothelial cells and endothelial injury, with a resultant prothrombotic state in the pulmonary vasculature.[49] Vascular endothelial injury causes further thrombocytopenia (through peripheral platelet destruction), a reduction in natural anticoagulants and haemostatic activation, and manifests as diffuse intravascular coagulation in COVID-19.[49]

**Multisystem inflammatory syndrome in children**

A rare but severe form of COVID-19 has been reported in children and is referred to as the multisystem inflammatory syndrome in children (MIS-C).[50] Clinical features of MIS-C are reported to be similar to but distinct from Kawasaki disease.

MIS-C is not an adult version of the CRS. Ongoing studies suggest that antibodies to SARS-CoV-2 actually permit viral entry into affected cells[51] or that immune complexes may be stimulatory to the immune system.[52] Cross-reactivity between a microbial antigen and host tissues, where epitopes are shared (molecular mimicry), is also a possibility.[53] Lastly, it is possible that SARS-CoV-2 may act as an adjuvant factor for the, as yet, unknown trigger in MIS-C.[54]

**Implications for therapy**

Multiple therapeutic strategies are being considered for patients with more severe COVID-19 and these are summarised in Table 1.[4-48,53-73] Some (in bold in the table) are effective and widely used therapies for severe COVID-19. The jury is still out as to the value of antiviral therapies. Recent trials using lopinivar/ritonavir as a single agent have shown no benefit. A variety of antiviral agents are being studied in various clinical trials.[54] A study published in The Lancet reported that remdesivir was not associated with a difference in time to clinical improvement (hazard ratio 1.23; 95% confidence interval (CI) 0.87 - 1.75).[55] In a subsequent study, in patients with symptom duration of 10 days or less, those treated with remdesivir had a numerically faster improvement (hazard ratio 1.23; 95% confidence interval (CI) 0.87 - 1.75).

![Table 1. Pharmacological modalities for treatment of COVID-19*](image)

| Pharmacological modality                                      | Mechanism of action                  | Benefit                                           | Reference                        |
|--------------------------------------------------------------|--------------------------------------|---------------------------------------------------|---------------------------------|
| Angiotensin–aldosterone system inhibitors, such as ARBs and ACE inhibitors | Blockade of SARS-CoV-2 receptor     | Only historical association studies being reported Conflicting studies Small studies | Adrish et al.[52] |
| Lopinivar/ritonavir                                           | Broad-spectrum antiviral             | None                                              | Conflicting studies             | Cao et al.[54] |
| Remdesivir                                                   | Antiviral                            | None                                              | Conflicting studies             | Wang et al.[52] Beigel et al.[54] |
| Favipiravir                                                   | Antiviral                            | None                                              | Conflicting studies             | Siemieniuk et al.[54] |
| Umifenovir                                                   | Antiviral                            | None                                              | Conflicting studies             | Siemieniuk et al.[54] |
| Tocilizumab                                                   | IL-6 receptor blockage              | Several ongoing RCTs                              | Menzella et al.[54]            |
| Anakinra                                                     | IL-1 monoclonal antibody             | Studies not completed or reported                 | Jamiloux et al.[54]            |
| Adalimumab                                                   | TNF-a monoclonal antibody            | Studies not completed or reported                 | Jamiloux et al.[54]            |
| Hydroxychloroquine                                           | Nonspecific anti-inflammatory        | None                                              | Molina et al.[54] Cortegiani et al.[54] |
| Zinc and nicotinic acid                                      | NAD+ precursors and SIRT1 activators | Unproven                                          | Wessels et al.[54]             |
| Vitamin D                                                    | Multiple scientific benefits         | Unproven                                          | Mark et al.[54]                |
| Vitamin C                                                    | Multiple scientific benefits         | Unproven                                          | Cheng et al.[54]               |
| Mesenchymal stromal/stem cell therapy                        | Counter inflammation and apoptosis   | Unproven                                          | Cao et al.[54] Gupta et al.[54] |
| Nutritional components including glutathione peroxidase, lipic acid, ferulic acid, sulforaphane, N-acetylcysteine, glyicine, citrulline and high-dose folate | Reducing NADPH oxidase dependent tissue factor expression | Unproven                          | Dnicolantonio and McCarty[49] |
| Intravenous immunoglobulin                                    | Immune boosting                      | Unproven                                          | Galeotti et al.[54]            |
| Corticosteroids                                              | Anti-inflammatory                    | Increasing evidence                                | Richards and Feldman[54]       |
| Convalescent serum                                           | Antibody boosting                    | One significantly positive study                  | Wu et al.[54]                  |
| Anticoagulation                                               | Reduce thrombi formation             | Positive results in severe disease                | Montelongo-Jauregui et al.[54] |

**Table 1.** Pharmacological modalities for treatment of COVID-19

ARBS = angiotensin II receptor blockers; ACE = angiotensin–converting enzyme; IL = interleukin; RCT = randomised controlled trial; TNF-a = tumour necrosis factor alpha; NAD+ = nicotinamide adenine dinucleotide; SIRT1 = silent information regulator 1; NADPH = NAD phosphate.

*Effective and widely used therapies for severe COVID-19 shown in bold.*

---

**Table 1.** Pharmacological modalities for treatment of COVID-19

| Pharmacological modality                                      | Mechanism of action                  | Benefit                                           | Reference                        |
|--------------------------------------------------------------|--------------------------------------|---------------------------------------------------|---------------------------------|
| Angiotensin–aldosterone system inhibitors, such as ARBs and ACE inhibitors | Blockade of SARS-CoV-2 receptor     | Only historical association studies being reported Conflicting studies Small studies | Adrish et al.[52] |
| Lopinivar/ritonavir                                           | Broad-spectrum antiviral             | None                                              | Conflicting studies             | Cao et al.[54] |
| Remdesivir                                                   | Antiviral                            | None                                              | Conflicting studies             | Wang et al.[52] Beigel et al.[54] |
| Favipiravir                                                   | Antiviral                            | None                                              | Conflicting studies             | Siemieniuk et al.[54] |
| Umifenovir                                                   | Antiviral                            | None                                              | Conflicting studies             | Siemieniuk et al.[54] |
| Tocilizumab                                                   | IL-6 receptor blockage              | Several ongoing RCTs                              | Menzella et al.[54]            |
| Anakinra                                                     | IL-1 monoclonal antibody             | Studies not completed or reported                 | Jamiloux et al.[54]            |
| Adalimumab                                                   | TNF-a monoclonal antibody            | Studies not completed or reported                 | Jamiloux et al.[54]            |
| Hydroxychloroquine                                           | Nonspecific anti-inflammatory        | None                                              | Molina et al.[54] Cortegiani et al.[54] |
| Zinc and nicotinic acid                                      | NAD+ precursors and SIRT1 activators | Unproven                                          | Wessels et al.[54]             |
| Vitamin D                                                    | Multiple scientific benefits         | Unproven                                          | Mark et al.[54]                |
| Vitamin C                                                    | Multiple scientific benefits         | Unproven                                          | Cheng et al.[54]               |
| Mesenchymal stromal/stem cell therapy                        | Counter inflammation and apoptosis   | Unproven                                          | Cao et al.[54] Gupta et al.[54] |
| Nutritional components including glutathione peroxidase, lipic acid, ferulic acid, sulforaphane, N-acetylcysteine, glyicine, citrulline and high-dose folate | Reducing NADPH oxidase dependent tissue factor expression | Unproven                          | Dnicolantonio and McCarty[49] |
| Intravenous immunoglobulin                                    | Immune boosting                      | Unproven                                          | Galeotti et al.[54]            |
| Corticosteroids                                              | Anti-inflammatory                    | Increasing evidence                                | Richards and Feldman[54]       |
| Convalescent serum                                           | Antibody boosting                    | One significantly positive study                  | Wu et al.[54]                  |
| Anticoagulation                                               | Reduce thrombi formation             | Positive results in severe disease                | Montelongo-Jauregui et al.[54] |

**Table 1.** Pharmacological modalities for treatment of COVID-19

ARBS = angiotensin II receptor blockers; ACE = angiotensin–converting enzyme; IL = interleukin; RCT = randomised controlled trial; TNF-a = tumour necrosis factor alpha; NAD+ = nicotinamide adenine dinucleotide; SIRT1 = silent information regulator 1; NADPH = NAD phosphate.

*Effective and widely used therapies for severe COVID-19 shown in bold.*
time to clinical improvement compared with those receiving placebo (hazard ratio 1.52; 95% CI 0.95 - 2.43).¹⁰

Several clinical trials have assessed the efficacy of hydroxychloroquine (alone or in combination) based on its nonspecific anti-inflammatory effects seen in other conditions. Data generated thus far indicate that it lacks efficacy and there may be safety concerns related to its use.¹⁰

Trials are under way to assess the potential benefits of therapies that block IL-6, its receptor, IL-1β, and GM-CSF, as well as other myeloid-derived inflammatory cytokines, especially TNF-α. IL-1 is a crucial element in the development of the CRS in patients with severe disease. Anakinra (an IL-1 antagonist) has been shown to be of benefit in patients with severe sepsis complicated by macrophage activation syndrome (MAS); studies with anakinra in COVID-19 may be useful to further understand the disease process, as well as providing a potential therapeutic option.¹²

TNF-α is one of the major drivers of inflammatory responses. TNF-α antagonistic drugs are used widely in management of rheumotological diseases. TNF-α levels are moderately elevated in SARS-CoV-2 patients. Targeting TNF-α has thus been identified as a potential therapeutic option, and clinical trials have been initiated to assess the effect of adalimumab, an anti-TNF monoclonal antibody.¹³ Strategies to interfere with receptor binding and cytokine signalling may unveil crucial pathogenetic mechanisms and possibly therapeutic options to prevent severe disease.

It is possible that high-dose intravenous immunoglobulin (IVIg) may have a beneficial effect in the hyperinflammatory phase but the mechanism of action is not known.¹⁰,¹⁴ It is particularly widely used in children with MIS-C.

Several nutritional components may have theoretical, but as yet untested, benefits in reducing NADPH oxidase dependent TF expression, including glutathione peroxidase, lipoic acid, ferulic acid, sulforaphane, N-acetylcysteine, glycine, citrulline and high-dose folate.¹⁵ Studies are planned or are under way to identify nutritional supplements which may help with NAPDH reduction as part of the treatment regimen in COVID-19.¹⁶

The use of corticosteroids for the treatment of COVID-19, based on their ability to suppress an exaggerated inflammatory response, has been widely deliberated in medical literature. Currently corticosteroid use for treatment of COVID-19 is recommended, mostly based on evidence from the RECOVERY trial (Randomized Evaluation of COVID Therapy).¹⁷ The RECOVERY trial reported that the use of corticosteroids (dexamethasone and methylprednisolone) reduced the risk of mortality, the need for mechanical ventilation and duration of hospital stay.¹⁷ It is important to note that corticosteroids have shown no benefit in patients who do not require respiratory support.¹⁷

The Surviving Sepsis Guideline (SSG) for COVID-19 recommends the use of low-dose corticosteroids in COVID-19 patients with shock who are not responding to treatment and in patients requiring mechanical ventilation, while it advises against steroid use for patients with COVID-19 in respiratory failure but without ARDS.¹⁷ Studies from China propose the use of corticosteroids early in COVID-19 based on the observation of reduced disease escalation and improved outcomes.¹⁷

Randomised clinical trials on the treatment of children with MIS-C have not been reported but certain therapies are widely used, including systemic steroids, high-dose IVIg and cytokine inhibitors. In addition, patients require respiratory and inotropic support.¹⁷

Conclusions

The disease course of COVID-19, including its molecular and mechanistic components, is becoming clearer. Three distinct stages of clinical progression based on immunological parameters have been described. The first involves an antiviral response with an immediate potent interferon release which brings the infection under control and potentially eradicates the virus. During the second stage, a delayed interferon response may ensue which would nonetheless result in extensive damage. If the second stage fails to achieve infection resolution, there is progression to a more severe third stage in which hyperinflammation with dysregulated macrophage activation and widespread coagulopathy ensues. Patients who progress to stage three may also have dysregulated repair mechanisms and fibrosis.¹⁸ The systemic hyperinflammation seen in patients infected with SARS-CoV-2 is believed by many to be the nidus of the pathology in severe disease, although a clearer definition of the CRS, particularly in relation to other causes, is needed. It is critical that the pathways involved in these stages are understood in order to develop appropriate treatment strategies.

Declaration. None.

Acknowledgements. None.

Author contributions. The authors contributed equally to writing the manuscript, and have read and agreed to the published version.

Funding. This work was supported by grants from the South African Research Council Extramural Unit for Stem Cell Research and Therapy, and the Institute for Cellular and Molecular Medicine of the University of Pretoria (MSP).

Conflicts of interest. None.
21. Cisco S, Cicco G, Rusconi V, Vacca A. Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): Two potential targets for COVID-19 treatment. Mediators Inflamm. 2020;2020:778-793. [Epub ahead of print]. https://doi.org/10.1155/2020/778793

22. Feldmann M, Ruini BN, Woods SN. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10240):1407-1409. https://doi.org/10.1016/S0140-6736(20)30888-8

23. Tang Y, Chen S, Li J, et al. Plasma IL-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 - J Allergy Clin Immunol. 2020;146(1):119-127.e2. https://doi.org/10.1016/j.jaci.2020.04.027

24. Samit Portunzi, S. Langer, L. Steiner, et al. Covid-19, cytokines and immunosuppression: What can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(6):337-342. PMID:33024888

25. Melita E, McAleary DE, Brown M, et al. Covid-19: Cytokine storm syndrome and immunosuppression. Lancet. 2020;395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30828-0

26. Soina P, Mattila MA, Callies CS. Is a ‘cytokine storm’ relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152-1154.(Epub ahead of print 30 June 2020). https://doi.org/10.1001/jamainternmed.2020.3313

27. Russel BD, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19: a systematic review of current evidence. ecmcancermedicine. 2020;14:1012. https://doi.org/10.1007/s41577-020-00407-w

28. Tay MZ, Poh CM, Rina L, et al. Covid-19: The known mechanisms and clinical effects. Front Immunol. 2020;11:1712. https://doi.org/10.3389/fimmu.2020.01712

29. Marko PE, Kory P, Varej J. Dose-virus D status impact mortality from SARS-CoV-2 infection? Med Drug Discov. 2020;29:435-439. [Epub ahead of print]. https://doi.org/10.1056/NEJMoa2002680

30. Liu S, Emadi MJ, Bumad M, et al. Optimal unified approach for rare-variant association testing with application to small-scale case-control whole-exome sequencing studies. Am J Human Genetics. 2012;91(2):224-57. https://doi.org/10.1016/j.ajhg.2012.02.007

31. Shortt K, Chandrahu S, Greigere D, et al. Identification of novel single nucleotide polymorphisms associated with acute respiratory diseases syndrome by case-control study. J Hum Genet. 2011;56(1):41-17. https://doi.org/10.1538/jhg.1009153

32. Ellingham D, Ferguson N, Mitra A, et al. The association of ABO blood group with incidence of disease severity and multimorgan dysfunction in COVID-19. Blood Cells Mol Dis. 2020;106:101962. https://doi.org/10.1016/j.bcmd.2020.101962

33. Botto CA, DeCarlo C, Bonito L, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(6):1411-1416. https://doi.org/10.1007/s00277-020-00414-1

34. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, Haematol 2020;Jul 12:1-6.(Epub ahead of print). https://doi.org/10.1007/s00277-020-04169-1

35. Bracht HE, Lindhout S, de Groot E, et al. Reducution prevalence of SARS-CoV-1 infection in ABO blood group O. Blood. 2020;4(490-499). https://doi.org/10.1182/bloodadvances.202002632

36. Burchardt T, Muller B, Schuppler H, et al. Idiopathic pulmonary fibrosis and COVID-19: a report of 2 cases. BMJ Case Rep. 2020;2020:10253. https://doi.org/10.1136/bcr-2020-237692

37. Lutz CA, DeCarlo C, Bonito L, et al. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(6):1411-1416. https://doi.org/10.1007/s00277-020-00414-1

38. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiopathy in Covid-19. N Engl J Med. 2020;382(20):2020-2031. PMID:32664342

39. Cral F, Murer M, Jakob J, et al. Venous thromboembolism in SARS-CoV-2 infected patients: Only a problem in ventilated ICU patients, or is there to move it to EAR Eire J Med. 2020;56(20). https://doi.org/10.1016/j.earj.2020.05.1357

40. Pang Y, Coutts J, Caplan M, et al. COVID-19 and Kawasaki disease: An etiology or coincidental infection. Pediatr Rev. 2020;42(3):134-135. https://doi.org/10.1542/ped.2020-1343I

41. Disselkotter JJ, McClymont K. Thrombosis complication of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endothelial PAC1P endocytosis. J Am Heart Assoc. 2020;2020:1195(11).198. https://doi.org/10.1161/jaha.120.110562

42. Connors IM, Levy JO. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. https://doi.org/10.1182/blood.2020009060

43. Hendrickx C, Houten F, green RJ, pepper MJ. Paediatric multiorgan inflammatory syndrome. S Afr Med J. 2020;110(9):832-844. https://doi.org/10.7196/SAMJ.v110.i15.15062